Evidence map›Paper›PMID 41613119›Full record

ArticleFrontiers in immunology2025

Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition.

Xi Zhu, Xiaopei Cui, Haijia Yu, Jingen Xu, Xiaofang Chen, Xiaochen Ren, Xiaoyue Wei, Shi Chen, Yangtin Wang, Liyang Fei and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Xi Zhu *Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Xiaopei Cui *Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Haijia Yu *Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Jingen Xu *Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Xiaofang ChenDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Xiaochen RenDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Xiaoyue WeiDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Shi ChenDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Yangtin WangDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Liyang FeiDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Bin XieDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Mingwei LiDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Xue LiDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Huifeng JiaDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Yujie FengDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Simin XiaDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Li ChenDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Yong ChengDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Lei ZhangDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Haidong LiCollege of Biology and Pharmacy, Yulin Normal University, Yulin, China.
Xiangyang ZhuDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Yifan ZhanDrug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combination therapy targeting the PD-1/PD-L1 and TIGIT pathways has been explored to enhance the efficacy of current immunotherapies. In this study, we investigated strategies to further potentiate the co-blockade of PD-L1 and TIGIT for cancer immunotherapy. Firstly, we demonstrated that the bispecific antibody (HB0036) for PD-L1 and TIGIT co-blockade induced a greater T-cell proliferative response

Indexed as

Antibodies, BispecificB7-H1 AntigenNeoplasmsReceptors, ImmunologicVascular Endothelial Growth Factor AAnimalsCell Line, TumorCombined Antibody TherapeuticsFemaleHumansImmune Checkpoint InhibitorsImmunotherapyMiceReceptors, VirusT Lineage-Specific Activation Antigen 1Tumor MicroenvironmentAntibodies, BispecificB7-H1 AntigenCombined Antibody TherapeuticsImmune Checkpoint Inhibitorspoliovirus receptorReceptors, ImmunologicReceptors, VirusT cell Ig and ITIM domain protein, mouseTIGIT protein, humanT Lineage-Specific Activation Antigen 1Vascular Endothelial Growth Factor Abispecific antibodycombination (combined) therapyPD-(L)1TIGITTME (tumor microenvironment)Treg - regulatory T cellVEGF

Identifiers

PMID41613119
PMCPMC12847297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.